Innate Pharma Collaborates with IFLI to Advance Follicular Lymphoma Drug IPH6501 Development

Innate Pharma Partners with IFLI to Advance Follicular Lymphoma Treatment

Innate Pharma SA has announced a significant collaboration with the Institute for Follicular Lymphoma Innovation (IFLI) to enhance the clinical development of its investigational drug, IPH6501, an anti-CD20 ANKET®. This partnership strategically aligns with Innate's ongoing Phase 1/2 open-label, multicenter trial, which is designed to evaluate the safety, tolerability, and preliminary anti-cancer activity of IPH6501 in patients suffering from relapsed or refractory Non-Hodgkin Lymphoma (NHL). With this new collaboration, the trial will specifically target patients with relapsed or refractory follicular lymphoma (FL), a subtype of NHL that poses significant treatment challenges.

The collaboration is propelled by an initial investment of $3 million from IFLI into new shares of Innate, priced at €1.56 per share, representing approximately 2.26% of Innate’s share capital. The financial support is intended to facilitate the trial’s expansion and enhance the development of IPH6501 as a viable treatment option for FL. Moreover, IFLI has the opportunity to invest an additional $4.9 million, contingent on the achievement of specific milestones in the clinical trial. This level of financial commitment underscores IFLI's confidence in the potential of IPH6501 to make a meaningful impact on patient outcomes in FL.

Dr. Sonia Quaratino, Chief Medical Officer at Innate, emphasizes the company's commitment to improving treatment outcomes for patients with Non-Hodgkin Lymphoma. She highlights that this collaboration is pivotal in addressing the urgent therapeutic needs within this patient population. Dr. Michel Azoulay from IFLI echoes this sentiment, asserting that the partnership exemplifies how philanthropic investments can accelerate advancements in treatment for follicular lymphoma. As a non-profit organization, IFLI focuses on fostering innovative therapies and enhancing collaboration among researchers to improve understanding and treatment options for FL. The partnership between Innate and IFLI represents a promising development in the quest for effective therapies for follicular lymphoma patients.

The ongoing collaboration not only reinforces Innate Pharma's commitment to oncology but also reflects IFLI’s mission to catalyze research and innovation in the treatment of follicular lymphoma. As the trial progresses, both organizations aim to generate valuable clinical data that may lead to improved therapeutic strategies for this challenging form of cancer. The partnership is a noteworthy example of how strategic alliances in the biopharmaceutical industry can mobilize resources and expertise to address critical healthcare needs.